Systematic review and meta-analysis on the prophylactic role of non-steroidal anti-inflammatory drugs to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis

Table 2 Summary and strength of the evidence from trials analysed on GradePro^®

Author(s): Sajid et al
Date: 20/10/2015
Question: NSAID’s are an effective modality to reduce the incidence of post-ERCP pancreatitis?
Settings: All patients undergoing booth elective or emergency ERCP in endoscopy department for any indication by an experienced gastroenterologist/endoscopists
Bibliography: Adapted from the Cochrane Database of Systematic Reviews [2015, Issue (Is)]
Quality assessment							No. of patients		Effect		Quality	Importance
No. of studies	Design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	NSAID's vs placebo	Control	Relative(95%CI)	Absolute
Incidence of overall pancreatitis (follow-up mean 3 mo; assessed with: Odds ratio)
14	Randomised trials	Serious	No serious inconsistency	No serious indirectness	No serious imprecision	Strong association	138/1900	248/1878	OR 0.49 (0.36 to 0.67)	63 fewer per 1000 (from 40 fewer to 80 fewer)	High	Critical
							(7.3%)	(13.2%)
								15.7%		73 fewer per 1000 (from 46 fewer to 94 fewer)

NSAIDs: Non-steroidal anti-inflammatory drugs; ERCP: Endoscopic retrograde cholangio-pancreaticography.